Cognoptix Raises over $15 Million to Fund Pivotal Clinical Trial and Final Product Development of Eye Test Designed to Identify Early-Stage Alzheimer's Disease
1 minutes ago - BusinessWire via Dow Jones News
Over-subscribed Series D round co-led by Alopexx Enterprises LLC and Inventages "Our clinical trial results strongly suggest that the Cognoptix SAPPHIRE II eye test may alter the course of Alzheimer's Disease by enabling early, reliable and cost-effective diagnosis of the disease at point-of-care."